OncoSec Medical Inc (NASDAQ:ONCS) Director Alpha Holdings, Inc. acquired 491,000 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was bought at an average cost of $3.14 per share, with a total value of $1,541,740.00. Following the acquisition, the director now owns 10,491,000 shares in the company, valued at $32,941,740. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
NASDAQ ONCS opened at $2.49 on Monday. OncoSec Medical Inc has a twelve month low of $2.34 and a twelve month high of $19.60.
ONCS has been the subject of several analyst reports. Zacks Investment Research raised OncoSec Medical from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Friday, March 15th. Maxim Group reaffirmed a “buy” rating and issued a $50.00 price target on shares of OncoSec Medical in a report on Monday, April 1st. Finally, ValuEngine raised OncoSec Medical from a “hold” rating to a “buy” rating in a report on Wednesday, May 22nd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $31.25.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in OncoSec Medical by 98.2% in the 4th quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock worth $311,000 after purchasing an additional 240,843 shares during the period. Moloney Securities Asset Management LLC raised its holdings in OncoSec Medical by 117.4% in the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 27,000 shares during the period. Northern Trust Corp raised its holdings in OncoSec Medical by 33.6% in the 4th quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 28,914 shares during the period. Geode Capital Management LLC raised its holdings in OncoSec Medical by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 163,405 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in OncoSec Medical by 484.1% in the 4th quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 83,150 shares during the period. 7.07% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Alpha Holdings, Inc. Buys 491,000 Shares of OncoSec Medical Inc (ONCS) Stock” was first reported by Zolmax and is the sole property of of Zolmax. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://zolmax.com/investing/alpha-holdings-inc-buys-491000-shares-of-oncosec-medical-inc-oncs-stock/3096509.html.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Recommended Story: How does a margin account work?
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.